Press release

Combined Shareholders’ Meeting of Ipsen S.A.
held on 27 May 2011

Adoption of all resolutions submitted to the Shareholders’ vote.

Paris (France), 27 May 2011 – The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN ; ADR: IPSEY) was held today, chaired by Mr. Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, in the presence of the Board of Directors and the Group’s management.

The Shareholders’ Meeting approved all resolutions proposed by the Board of Directors and in particular:

- the distribution of a €0.80 dividend per share to be paid on 6 June 2011 (ex-dividend date 1 June 2011)
- the ratification of the cooptation of Mr. Marc de Garidel,
- the amendment of the Company bylaws on the length of directors’ term of office from three to four years and allowing the implementation of staggering of terms of offices,
- the appointment of Mr. Christophe Vérot as a Director for a four-year term, which shall expire at the conclusion of the Shareholders’ Meeting to be held in 2015 called to approve the financial statements for the previous financial year,
- the renewal of the terms of office of Messrs. Marc de Garidel and Henri Beaufour as Directors for a four-year term, which shall expire at the conclusion of the Shareholders’ Meeting to be held in 2015 called to approve the financial statements for the previous financial year,
- the renewal of the terms of office of Mrs. Anne Beaufour and Messrs. Hervé Couffin and Pierre Martinet as Directors for a three-year term, which shall expire at the conclusion of the Shareholders’ Meeting to be held in 2014 called to approve the financial statements for the previous financial year,
- the renewal of the terms of office of Messrs. Antoine Flochel, Gérard Hauser and Klaus-Peter Schwabe as Directors for a two-year term, which shall expire at the conclusion of the Shareholders’ Meeting to be held in 2013 called to approve the financial statements for the previous financial year,
- the renewal of the terms of office of Messrs. René Merkt and Yves Rambaud as Directors for a one-year term, which shall expire at the conclusion of the Shareholders’ Meeting to be held in 2012 called to approve the financial statements for the previous financial year.

During the meeting, Marc de Garidel and Claire Giraut, Executive Vice-President, Chief Financial Officer, notably presented the major events and financial results for 2010, the Group’s 2011 financial objectives and 2011 first quarter sales.

After the Shareholders’ Meeting, the Board of Directors approved, in particular, the renewal of Mr. Marc de Garidel as Chairman and Chief Executive Officer and Mr. Antoine Flochel as Vice-Chairman of the Board of Directors as well as the composition of the Board Committees.
About Ipsen
Ipsen is a global biopharmaceutical group, with sales exceeding €1.1 billion in 2010. The Group has total worldwide staff of more than 4,400 employees, of which more than 900 contribute to the discovery and development of innovative drugs for patient care. Ipsen’s development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology and on primary care drugs. This strategy is supported by an active policy of partnerships. Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

For further information:

Media
Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com

Financial Community
Pierre Kemula
Investor Relations Officer
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
E-mail: pierre.kemula@ipsen.com

Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com